Clinical Trials Logo

Flushing clinical trials

View clinical trials related to Flushing.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03508869 Terminated - Clinical trials for Erythema and Flushing Associated With Rosacea

Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

Start date: September 27, 2016
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of Rosacea.

NCT ID: NCT02492477 Terminated - Solid Tumours Clinical Trials

TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients

Start date: January 2016
Phase: Phase 1
Study type: Interventional

The benefits and risks of flushing or not flushing the non-used PORT-A-CATH® in cancer patients and the time interval of eventual PORT-A-CATH® flushing are currently unknown. The manufacturers of PORT-A-CATH® recommend regular flushings every 4 weeks. In clinical practice, the intervals are usually at least three months. Regular flushing might lead to a decreased risk of PORT-A-CATH® thrombosis, but may also lead to an increased infection or thrombosis rate and patients discomfort. Therefore, this study investigates the safety of not flushing the PORT-A-CATH® for 6 or 12 months.

NCT ID: NCT02277210 Terminated - Infertility Clinical Trials

Follicular Flushing in Patients With Suboptimal Responses

Start date: October 2014
Phase: N/A
Study type: Interventional

The aim of the present study is to determine the effect of follicular flushing on the ongoing pregnancy rate in patients who developed four or fewer follicles of 14mm following standard ovarian stimulation for IVF.

NCT ID: NCT02032862 Terminated - Clinical trials for Menopausal Hot Flushes

Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating

Start date: December 2013
Phase: Phase 4
Study type: Interventional

Sage tablets ( 3400 mg extract from fresh sage leaves, DER 1:17) in a once daily application over 12 treatment weeks are compared against placebo in 200 menopausal patients with ≥ 5 hot flushes daily and a Hyperhidrosis Scale score ≥ 2